The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
Authors:
- Belen Lopez-MillanBLBelen Lopez-Millan
- Paula CostalesPCPaula Costales
- Francisco Gutiérrez-AgüeraFGFrancisco Gutiérrez-Agüera
- Rafael Díaz de la GuardiaRGRafael Díaz de la Guardia
- Heleia Roca-HoHRHeleia Roca-Ho
- Meritxell VinyolesMVMeritxell Vinyoles
- Alba Rubio-GayarreARAlba Rubio-Gayarre
- Rémi SafiRémi Safi
- Julio CastañoJCJulio Castaño
- Paola Alejandra RomecínPRPaola Alejandra Romecín
- Manuel Ramírez-OrellanaMRManuel Ramírez-Orellana
- Eduardo AnguitaEduardo Anguita
Open Access
Abstract
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Patients with AML harboring a constitutively active internal tandem duplication mutation (ITDMUT) in the FMS-like kinase tyrosine kinase (FLT3) receptor generally have a poor prognosis. Several tyrosine kinase/FLT3 inhibitors have been developed and tested clinically, but very few (midostaurin and gilteritinib) have thus far been FDA/EMA-approved for patients with newly diagnosed or relapse/refractory FLT3-ITDMUT AML. Disappointingly, clinical responses are commonly partial or not durable, highlighting the need for new molecules targeting FLT3-ITDMUT AML. Here, we tested EC-70124, a hybrid indolocarbazole analog from the same chemical space as midostaurin with a potent and selective inhibitory effect on FLT3. In vitro, EC-70124 exerted a robust and specific antileukemia activity against FLT3-ITDMUT AML primary cells and cell lines with respect to cytotoxicity, CFU capacity, apoptosis and cell cycle while sparing healthy hematopoietic (stem/progenitor) cells. We also analyzed its efficacy in vivo as monotherapy using two different xenograft models: an aggressive and systemic model based on MOLM-13 cells and a patient-derived xenograft model. Orally disposable EC-70124 exerted a potent inhibitory effect on the growth of FLT3-ITDMUT AML cells, delaying disease progression and debulking the leukemia. Collectively, our findings show that EC-70124 is a promising and safe agent for the treatment of AML with FLT3-ITDMUT.Keywords
This publication has 51 references indexed in Scilit:
- Cord blood-derived CD34+ hematopoietic cells with low mitochondrial mass are enriched in hematopoietic repopulating stem cell functionHaematologica, 2013
- FLT3 inhibition: a moving and evolving target in acute myeloid leukaemiaLeukemia, 2012
- Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivoOncogene, 2011
- FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotypeHaematologica, 2011
- Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity ComparisonGenes & Cancer, 2010
- Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapseLeukemia Research, 2010
- Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazolesChemical Communications, 2009
- NG2 antigen is expressed in CD34+ HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered?Leukemia, 2008
- Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathwaysBlood, 2006
- Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell linesOncogene, 2000